97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00048347 (ClinicalTrials.gov) | October 2002 | 29/10/2002 | Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis | An Open-Label, Pilot Study of Type I Interferon (AVONEX) Treatment of Ulcerative Colitis | Ulcerative Colitis | Drug: AVONEX | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | N/A | All | 18 | Phase 2 | United States |
| 2 | NCT00303381 (ClinicalTrials.gov) | December 2001 | 14/3/2006 | Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis | A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutaneously Administered IFN-beta-1a in the Treatment of Patients With Moderately Active Ulcerative Colitis | Ulcerative Colitis | Drug: Interferon-beta-1a, 44 microgram;Drug: Placebo;Drug: Interferon-beta-1a, 66 microgram | EMD Serono | Merck Serono International SA | Completed | 18 Years | N/A | Both | 194 | Phase 2 | Germany;Israel;Netherlands;Singapore;Sweden;Switzerland;United Kingdom;Spain |